Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, a diagnosis of AD depends on the clinical symptoms of dementia, magnetic resonance imaging to determine brain volume, and positron emission tomography imaging to detect brain amyloid or tau deposition. The best characterized biological fluid markers for AD are decreased levels of amyloid β-protein (Aβ) 42 and increased levels of phosphorylated tau and total tau in cerebrospinal fluid (CSF). However, less invasive and easily detectable biomarkers for the diagnosis of AD, especially at the early stage, are still under development. Here, we provide an overview of various biomarkers identified in CSF and blood for the diagnostics of AD over the last 25 years. CSF biomarkers that reflect the three hallmarks of AD, amyloid deposition, neurofibrillary tangles, and neurodegeneration, are well established. Based on the need to start treatment in asymptomatic people with AD and to screen for AD risk in large numbers of young, healthy individuals, the development of biomarkers for AD is shifting from CSF to blood. Elements of the core pathogenesis of AD in blood, including Aβ42, tau proteins, plasma proteins, or lipids have shown their usefulness and capabilities in AD diagnosis. We also highlight some novel identified blood biomarkers (including Aβ42/Aβ43, p-tau 181, Aβ42/APP669-711, structure of Aβ in blood, and flotillin) for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“An FAD cohort study from the Dominantly Inherited Alzheimer Network indicated that CSF Aβ42 levels may first increase and then start to decline 25 years before the onset of AD symptoms, whereas amyloid deposition measured with PET and Pittsburgh compound B and an increased concentration of t-tau in the CSF can be dete…”
BackgroundAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“The core pathogenic molecules for AD, Aβ42, total tau (t-tau), and p-tau in CSF, were studied beginning in the 1990s and have become reliable and sensitive biomarkers for AD diagnosis [20,21].”
BackgroundHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“CSF is thus the optimal source for AD biomarkers [19].”
Background
Cited by
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
“Some proteins related to the two biomarkers detected in the peripheral blood are attractive candidates for AD diagnosis [8–12] because they are contained in the amyloid cascade hypothesis, which introduces the idea that A β misfolding and deposition are the primary precipitants of AD [4,5].”
BackgroundGarcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
“At present, AD diagnosis is based on the existence of dementia, brain volume changes detected by magnetic resonance imaging (MRI), and brain amyloid βprotein (Aβ) or Tau deposition detected by positron emission tomography (PET), together with an Aβ42 decrease and a phosphorylated/total Tau increase in the cerebrospina…”
BackgroundPhosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
Qin, W., Li, F., Jia, L., Wang, Q., Li, Y., Wei, Y., Li, Y., Jin, H., & Jia, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.900773 · Cited by 23
“Total Tau and p-Tau181 isoform levels were significantly increased in the CSF of AD patients (Dubois et al., 2014; Molinuevo et al., 2018; Zou et al., 2020).”
Background
Metadata
- Authors
- Zou, K., Abdullah, M., & Michikawa, M.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2020-08-12
- Volume
- 10
- Issue
- 3
- Pages
- 85
- ISSN
- 2075-4426 (ISSN-L)
- OpenAlex
- W3048923498
- Cited by
- 83
- References
- 43
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Biomarkers for Alzheimer’s Disease: From CSF to Blood. https://app.cochat.ai/papers/10.3390/jpm10030085
- The paper
- Zou, K., Abdullah, M., & Michikawa, M. (2020). Current Biomarkers for Alzheimer’s Disease: From CSF to Blood. Journal of Personalized Medicine. https://doi.org/10.3390/jpm10030085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.